@EORTC_HNCG_YI (@eortcy) 's Twitter Profile
@EORTC_HNCG_YI

@eortcy

ID: 1489605115019509766

calendar_today04-02-2022 14:25:08

199 Tweet

191 Followers

232 Following

@EORTC_HNCG_YI (@eortcy) 's Twitter Profile Photo

Do not miss the Y-ECI session at the HNCG meeting this Saturday 27.04.2024 at 11 am CET. See the agenda below 🤓👩‍⚕️👨‍⚕️

Do not miss the Y-ECI session at the HNCG meeting this Saturday 27.04.2024 at 11 am CET. See the agenda below 🤓👩‍⚕️👨‍⚕️
@EORTC_HNCG_YI (@eortcy) 's Twitter Profile Photo

📣 Our review and metanalysis on IO in elderly HNSCC pts is now out! First paper coming from the EORTC HNCG YI group 🤓☺️ led by ⁦Viola Salvestrini⁩ and Petr Szturz. Check it out 👇🏻 frontiersin.org/journals/oncol…

Pablo Jiménez (@pauljil) 's Twitter Profile Photo

📢Eager to see some of the most interesting abstracts on new therapies at this ASCO meeting in HNSCC field!Preliminary info 🔬Here my personal selection👇 ASCO OncoAlert TTCC-GrupoTratamiento Tumores Cabeza y Cuello

📢Eager to see some of the most interesting abstracts on new therapies at this ASCO meeting in HNSCC field!Preliminary info
🔬Here my personal selection👇 
<a href="/ASCO/">ASCO</a> <a href="/OncoAlert/">OncoAlert</a> <a href="/ttccgroup/">TTCC-GrupoTratamiento Tumores Cabeza y Cuello</a>
Benjamin Besse (@benjaminbessemd) 's Twitter Profile Photo

Important and completely counter intuitive study ! The NGR-LU002 stydy shows that the irradiation of all sites (primary+mets) after induction chemo or chemo-IO does not increase survival compared to the standard maintenance treatment. « Le mieux est l’ennemi du bien » #ASCO24

Important and completely counter intuitive study !
The NGR-LU002 stydy shows that the irradiation of all sites (primary+mets) after induction chemo or chemo-IO does not increase survival compared to the standard maintenance treatment.
« Le mieux est l’ennemi du bien » #ASCO24
@EORTC_HNCG_YI (@eortcy) 's Twitter Profile Photo

Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline - Practical Radiation Oncology practicalradonc.org/article/S1879-…

@EORTC_HNCG_YI (@eortcy) 's Twitter Profile Photo

🔈🔈interim analysis of Trilynx ph3 study: crossed the futility boundary 😵‍💫 emdgroup.com/en/news/xevina…

Michael Saerens (@msaerens01) 's Twitter Profile Photo

EORTC-1206: Double androgen blockade (bicalutamide + leuproreline) vs chemotherapy in AR+#salivaryglandcancer: ⛔️no benefit for frontline CAB, low response rates. Better to use combined or sequential approach? and what in HER2+ AR+ SGC? @EORTC_HNCG_YI ESMO - Eur. Oncology #ESMO2024

EORTC-1206: Double androgen blockade (bicalutamide + leuproreline) vs chemotherapy in AR+#salivaryglandcancer: ⛔️no benefit for frontline CAB, low response rates. Better to use combined or sequential approach? and what in HER2+ AR+ SGC? <a href="/EortcY/">@EORTC_HNCG_YI</a> <a href="/myESMO/">ESMO - Eur. Oncology</a> #ESMO2024
Michael Saerens (@msaerens01) 's Twitter Profile Photo

Did you know that around 700 000 people worldwide get #headandneckcancer, about 100 000 are attributed to #HPV infection. Prevention is the 🗝️to reduce cancer burden: stop tobacco 🚭& alcohol abuse, and increase vaccination rate 💉 Make Sense Campaign @EORTC_HNCG_YI

Did you know that around 700 000 people worldwide get #headandneckcancer, about 100 000 are attributed to #HPV infection. Prevention is the 🗝️to reduce cancer burden: stop tobacco 🚭&amp; alcohol abuse, and increase vaccination rate 💉
<a href="/MakeSenseCmpn/">Make Sense Campaign</a> <a href="/EortcY/">@EORTC_HNCG_YI</a>
@EORTC_HNCG_YI (@eortcy) 's Twitter Profile Photo

Stay tuned for Y-ECI session on Oct 12th 12 to 13.00 CET: agenda below 🤓👇🏻. Info on Registration can be found the cited tweet 😊

Stay tuned for Y-ECI session on Oct 12th 12 to 13.00 CET:  agenda below 🤓👇🏻. Info on Registration can be found the cited tweet 😊
ESMO - Eur. Oncology (@myesmo) 's Twitter Profile Photo

📣 New ESMO–EURACAN #ClinicalPracticeGuideline in #SinonasalMalignancy includes treatment advances in #radiotherapy focusing on #particletherapy and #neoadjuvantchemotherapy in high-grade, locally advanced malignancies. #ESMOGuidelines 🔗ow.ly/5UwW50UUEvj

📣 New ESMO–EURACAN #ClinicalPracticeGuideline in #SinonasalMalignancy includes treatment advances in #radiotherapy focusing on #particletherapy and #neoadjuvantchemotherapy in high-grade, locally advanced malignancies. #ESMOGuidelines

🔗ow.ly/5UwW50UUEvj
ESMO Open (@esmo_open) 's Twitter Profile Photo

Systematic review on individualization of systemic therapies for locoregionally advanced NPC in ESMO Open. Extensive review of available clinical data, while waiting for results of studies exploring personalized approaches to (de)escalate treatments. esmoopen.com/article/S2059-…

Systematic review on individualization of systemic therapies for locoregionally advanced NPC in <a href="/ESMO_Open/">ESMO Open</a>. Extensive review of available clinical data, while waiting for results of studies exploring personalized approaches to (de)escalate treatments. esmoopen.com/article/S2059-…